Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Brain Tumor: early-phase trial registry
34 of 71 indexed Brain Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #197 of 28,707 conditions by registered trial count.
71 US clinical trials · 34 currently recruiting · #197 of 28,707 conditions by registered trial count
Brain Tumor: 71 US clinical trials tracked, 34 recruiting.
Brain Tumor is the subject of 71 registered US clinical trials on ClinicalTrials.gov, 34 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 6 of these trials.
Enrollment posture brief
Registry condition brain-tumor
OPEN 34 | RECR 48% | LATE 2 | EARLY 28 | RANK #197 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Aging (48% recruiting · 263 trials)
Brain Tumor lists 34 open slots (48% of 71 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Brain Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Brain Tumor is recruiting above its size-band peers.
34 of 71 indexed trials (47.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Brain Tumor trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 6 of 71 trials (8.5%). 43 distinct sponsors appear on at least one study for this condition label.
-
Most Brain Tumor trials plan to enrol fewer than 100 people.
Median target enrolment is 43 among the 70 trials that report a genuine target (sentinel values excluded). 51 of those (72.9%) plan for fewer than 100 participants.
-
Brain Tumor research is mostly interventional.
55 interventional and 16 observational studies make up this index (77.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
71 total, page 2 of 2
MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors
InSightec
NCT00147056
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
National Cancer Institute (NCI)
NCT02851706
Illness Management and Parental Adjustment to Cancer Treatment
Children's Hospital Medical Center, Cincinnati
NCT02505165
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Duke University
NCT00597402
Brain Tumor Patient-Caregiver Congruence, MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)
M.D. Anderson Cancer Center
NCT00748774
Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
Massachusetts General Hospital
NCT01063114
Safety and Feasibility of the Infinity Catheter for Radial Access
Rutgers, The State University of New Jersey
NCT04553549
In-Room PET in Proton Radiation Therapy
Massachusetts General Hospital
NCT01228448
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
University of Michigan Rogel Cancer Center
NCT02409121
The Good Patient Study
St. Jude Children's Research Hospital
NCT02199548
C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors
Virginia Commonwealth University
NCT05984667
Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant
St. Jude Children's Research Hospital
NCT01540175
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology
NCT04479241
PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors
howard safran
NCT00763750
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Katy Peters, MD, PhD
NCT02193347
Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors
University of Florida
NCT01111097
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
Monteris Medical
NCT00747253
GW572016 to Treat Recurrent Malignant Brain Tumors
National Cancer Institute (NCI)
NCT00107003
Neurosurgical Use of Interstitial Laser Therapy (ILT)
Brigham and Women's Hospital
NCT00207350
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
Memorial Sloan Kettering Cancer Center
NCT04173104
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT00019630
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 9 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Brain Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Brain Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Brain Tumor page
71 registered trials, 34 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 34 Brain Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Brain Tumor trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Brain Tumor condition card totals 71 registered trials; most-linked intervention Temozolomide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.